Cowen & Co. Thinks Bellerophon’s Stock is Going to Recover

By George MacDonald

Cowen & Co. analyst Ritu Baral reiterated an Outperform rating on Bellerophon (NASDAQ: BLPH) yesterday and set a price target of $12. The company’s shares closed yesterday at $2.40, close to its 52-week low of $1.90.

Baral observed, “BLPH is on track to initiate its Ph3 program of INOpulse in PAH in 2Q16 after finalizing.”

Bellerophon has an analyst consensus of Moderate Buy.

The company has a one year high of $10.88 and a one year low of $1.90. Currently, Bellerophon has an average volume of 46.57k.

Unlike Cowen & Co.`s latest rating, based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is neutral on the stock. Most recently, in December 2015, Jonathan Peacock, a the President & CEO of BLPH bought 20,300 shares for a total of $55,728.

According to, Baral is a 4-star analyst with an average return of 2.9% and a 34.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protalix Biotherapeutics, and Intra-Cellular Therapies.

Bellerophon Therapeutics LLC is a clinical-stage therapeutics company developing products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary and cardiac diseases.